Business
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions
ANN ARBOR, Mich., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical trials of bempedoic
About this update from Esperion Therapeutics, Inc.
[{"type":"text","content":"ANN ARBOR, Mich., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia on Sunday, November 17, 2019. Bempedoic acid is being developed as a cost-effective, convenient, once-daily, oral therapy for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C) added onto maximally tolerated statin therapy. Bempedoic acid and the bempedoic acid 180 mg + ezetimibe 10 mg fixed dose combination (FDC) tablet’s new drug applications (NDAs) are currently under regulatory review by the U.S. Food and Drug Administration (FDA), and the marketing authorisation applications (MAAs) are currently under centralized review by the European Medicines Agency (EMA).\n Esperion completed its global, pivotal, Phase 3 clinical development program and announced positive cumulative results in October 2018. The program evaluated the safety, tolerability and LDL-C-lowering efficacy of bempedoic acid and the bempedoic acid / ezetimibe combination tablets in patients with hypercholesterolemia who either have atherosclerotic cardiovascular disease (ASCVD) or are at high risk of ASCVD, and who continue to have elevated levels of LDL-C despite the use of maximally-tolerated statins and ezetimibe, leaving them at high risk for cardiovascular events. The program included over 4,000 patients across five studies, four for bempedoic acid. Details on the oral presentation are as follows: Title: Bempedoic Acid and Glycemic Control: A Pooled Analysis of 4 Phase 3 Clinical TrialsAuthor: Lawrence A Leiter, MD, FRCPC, FACP, FACE, FAHADate and Time: November 17, 2019 at 11:00 a.m. ETLocation: Science and Technology Hall A, Booth 605, Level 2, Pennsylvania Convention Center, Philadelphia, PA Details on the poster presentation are as follows: Title: Efficacy of Bempedoic Acid: A Pooled Analysis of 4 Pivotal Phase 3 Clinical TrialsAuthor: Maciej Banach, MD, PhD, FAHA, FESC, FNLA, FASA, FRSPHDate and Time: November 17, 2019 at 3:00 p.m. ETLocation: Zone 3, Science and Technology Hall, Pennsylvania Convention Center, Philadelphia, PA Bempedoic Acid Bempedoic acid is our lead, non-statin, oral, once-daily, low-density lipoprotein cholesterol (LDL-C) lowering therapeutic cand...